MK0787 vs Cefoperazone: 1982 Antibacterial Study

The reference article by Cullmann and colleagues examined the antibacterial profile of N-formimidoyl thienamycin, also known as MK0787, against a diverse collection of resistant clinical isolates. Published in Antimicrobial Agents and Chemotherapy in 1982, the study compared MK0787 with mezlocillin, cefuroxime, cefazedone, Cefoperazone, cefotaxime, and moxalactam. Rather than reporting a single potency value, the investigators assessed organism-specific activity, bactericidal behavior, and the apparent influence of β-lactamase production. The complete study is available through the reference paper.

Study Background and Research Question

At the time of the study, ampicillin-resistant Enterobacteriaceae and other difficult-to-treat gram-negative pathogens were creating a need for β-lactam agents with broader and more reliable activity. A major concern in gram-negative bacterial resistance was enzymatic inactivation by β-lactamases, which could make an apparently active compound unreliable across species or clinical isolates.

The research question therefore had several dimensions: How did MK0787 compare with recently developed β-lactams across resistant clinical isolates? Was its activity preserved against organisms producing β-lactamases? And did inhibition translate into bactericidal action, particularly against gram-negative bacilli and resistant staphylococci? The investigators designed the study to address these questions in parallel rather than treating the minimum inhibitory concentration, or MIC, as the only relevant endpoint.

Key Innovation from the Reference Study

The study’s innovation was its integrated comparative design. MK0787 was tested against multiple clinically important groups, including resistant Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter species, Streptococcus faecalis, and oxacillin-resistant Staphylococcus aureus. This enabled the authors to describe antibacterial activity against gram-negative bacilli in an organism-resolved way, revealing that a compound could be highly competitive against one group while being less active than another agent against a different group.

A second important feature was the analysis of killing in relation to inhibition. The authors reported whether MK0787 was bactericidal at concentrations close to the MIC, helping distinguish suppression of visible growth from actual reduction of viable bacteria. They also compared activity with β-lactamase production among gram-negative isolates. Although this was not a molecular study of individual enzymes or resistance genes, the approach connected susceptibility results with a clinically relevant resistance phenotype. That combination made the paper more informative than a simple ranking of MIC distributions.

Methods and Experimental Design Insights

The investigators used recent isolates collected from seven hospitals. The panel included 335 ampicillin-resistant Enterobacteriaceae, 50 P. aeruginosa strains, 28 Acinetobacter strains, 50 S. faecalis strains, and 7 oxacillin-resistant S. aureus strains. Enterobacteriaceae were identified with the API 20E system, while the other organisms were identified using standard procedures. The study-defined ampicillin resistance criterion for Enterobacteriaceae was an MIC greater than 16 µg/mL, and the oxacillin-resistant staphylococcal group was defined by an oxacillin MIC greater than 4 µg/mL, according to the original methods and isolate definitions.

Susceptibility testing used broth dilution in Mueller-Hinton broth with twofold serial drug dilutions. Microtiter plates were used with a final volume of 0.1 mL and an inoculum of 5 × 10⁵ colony-forming units per mL. The MIC was defined as the lowest concentration that suppressed visible growth. The comparison set included Cefoperazone and several other newer β-lactams, allowing relative rather than isolated interpretation of each result. MBC-related observations were then used to assess whether growth inhibition was accompanied by killing.

Protocol Parameters

• Isolate panel: Use a clearly defined collection of resistant clinical isolates and report organism-level sample sizes, as done for the five major groups in the reference study.
• Assay format: The published experiment used broth dilution in Mueller-Hinton broth with twofold serial dilutions and microtiter plates.
• Inoculum: The reported starting inoculum was 5 × 10⁵
• Primary endpoint: Record the MIC as the lowest concentration preventing visible growth, while keeping MIC and MBC analyses separate.
• Resistance interpretation: Treat β-lactamase production as a phenotypic comparison in this paper, not as proof of a specific enzyme, gene, or molecular pathway.

For a modern in vitro antimicrobial activity assay, the historical parameters are best used as a design reference. Contemporary standards, strain provenance, medium quality, inoculum verification, incubation conditions, and plate-reading criteria should be documented independently.

Core Findings and Why They Matter

MK0787 showed a broad and uneven spectrum. Against Escherichia coli and Enterobacter strains, its activity was comparable to cefotaxime in the study panel. It was less active than cefotaxime against Klebsiella, Serratia, and Proteus species. This distinction is important because it demonstrates why species-level susceptibility distributions are more informative than describing a β-lactam as simply broad spectrum.

Compared with the other agents, MK0787 was somewhat less active than moxalactam against most tested strains but was more active than mezlocillin, cefuroxime, and Cefoperazone across much of the gram-negative panel. The result should be interpreted as a comparative finding within this isolate collection, not as a universal clinical ranking. Differences in resistance prevalence, breakpoints, dosing exposure, and testing methodology can alter relative performance in later studies.

The clearest advantage for MK0787 appeared against P. aeruginosa and Acinetobacter species, where it was the most active drug among those evaluated. Its activity against S. faecalis was comparable to that of ampicillin, showing that the compound’s relevance was not restricted to gram-negative organisms. Against the seven oxacillin-resistant staphylococci, MK0787 inhibited the organisms at low concentrations; the reported MIC₉₀ was 0.25 µg/mL. However, it was not bactericidal at that MIC₉₀, emphasizing that low inhibitory concentration did not guarantee equivalent killing in the gram-positive subset. These findings are reported in the study results.

For all gram-negative isolates tested, MK0787 was bactericidal at concentrations below twice the MIC. The authors also observed that its antibacterial activity against gram-negative bacilli was independent of β-lactamase production. Together, these observations support the idea that MK0787 combined broad inhibitory coverage with strong killing against the gram-negative organisms examined. They do not, however, establish that all β-lactamases were equally unable to hydrolyze the drug, nor do they eliminate nonenzymatic resistance mechanisms such as altered permeability or target changes.

Comparison with Existing Internal Articles

The internal review Comparative Antibacterial Efficacy of Cefoperazone and MK0787 provides a concise interpretation of the same historical comparison, particularly the differences in spectrum, β-lactamase-related behavior, and bactericidal potential. Its value is contextual: the DOI-linked article remains the primary source for the isolate panel, assay conditions, and comparative observations.

A separate workflow-focused resource, Cefoperazone (sodium salt): Reliable Antibacterial Assay Solutions, is more relevant to planning laboratory susceptibility experiments with a cefoperazone reagent. It complements the reference study by addressing assay implementation, but it should not be used to infer historical MIC rankings or replace current susceptibility-testing standards.

Limitations and Transferability

The reference study has several limitations that affect how its results should be used today. First, it analyzed isolates collected in the early 1980s, before the current distribution of extended-spectrum β-lactamases, carbapenemases, and other resistance determinants. The phrase β-lactamase independence describes the authors’ observation in that collection; it is not a contemporary molecular classification.

Second, the isolate numbers were uneven across organism groups, with only seven oxacillin-resistant staphylococci. The results for that subset therefore provide useful signal but limited generalizability. Third, the work was an in vitro comparison. It did not measure pharmacokinetics, tissue penetration, toxicity, clinical outcomes, or pharmacodynamic target attainment. Consequently, the superior activity of MK0787 against Pseudomonas and Acinetobacter in this assay cannot by itself determine treatment selection.

For current research, the most transferable lesson is methodological: compare agents using a defined and relevant isolate panel, report organism-specific MIC distributions, distinguish inhibition from killing, and characterize resistance phenotypes alongside susceptibility. Researchers studying gram-negative bacterial resistance should also add contemporary genotypic and enzymatic analyses rather than assuming that a historical β-lactamase observation applies to modern isolates.

Research Support Resources

Researchers can use Cefoperazone (sodium salt) (SKU C3913) to support similar in vitro antimicrobial activity assay workflows. The product information describes it as a semisynthetic cephalosporin antibiotic and recommends storage at −20°C, with solutions prepared promptly rather than held long term. APExBIO’s current product page should be consulted for handling and preparation details before experimental use.